FOLH1 and pachyonychia congenita: In the PSMA-positive micrometastatic PC model, a similar 2-fold increase in median survival was observed with 740 kBq of 211At-PSMA-6 and with 18.5 MBq of 125I-DCIBzL; however, this represented 20 times the MTD for 211At-PSMA-6 compared with less than 1/6th of the MTD for 125I-DCIBzL.